MX2020011844A - Anticuerpos bispecificos con marcadores con emparejamiento de cargas c-terminales escindibles. - Google Patents

Anticuerpos bispecificos con marcadores con emparejamiento de cargas c-terminales escindibles.

Info

Publication number
MX2020011844A
MX2020011844A MX2020011844A MX2020011844A MX2020011844A MX 2020011844 A MX2020011844 A MX 2020011844A MX 2020011844 A MX2020011844 A MX 2020011844A MX 2020011844 A MX2020011844 A MX 2020011844A MX 2020011844 A MX2020011844 A MX 2020011844A
Authority
MX
Mexico
Prior art keywords
cleavable
domain
bispecific antibodies
terminal charge
paired tags
Prior art date
Application number
MX2020011844A
Other languages
English (en)
Inventor
Kevin Graham
Stephen Smith
Dante ROMANINI
Christopher Mohr
Kawooya John K
Agrawal Neeraj J
Jacobitz Alex W
Ray Lieh Yoon Low
Oliver Thiel
Victoria Wagner
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2020011844A publication Critical patent/MX2020011844A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se dirige a una molécula que contiene CH3 que comprende (a) un primer polipéptido que comprende un dominio CH3 y un dominio cargado negativamente que comprende restos de aminoácido cargados negativamente consecutivos; y (b) un segundo polipéptido que comprende un dominio CH3 y un dominio cargado positivamente que comprende restos de aminoácido cargados positivamente consecutivos. También se proporcionan métodos para conjugar moléculas sintéticas con una molécula de unión al antígeno multiespecífica.
MX2020011844A 2018-05-08 2019-05-08 Anticuerpos bispecificos con marcadores con emparejamiento de cargas c-terminales escindibles. MX2020011844A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862668626P 2018-05-08 2018-05-08
PCT/US2019/031379 WO2019217587A1 (en) 2018-05-08 2019-05-08 Bispecific antibodies with cleavable c-terminal charge-paired tags

Publications (1)

Publication Number Publication Date
MX2020011844A true MX2020011844A (es) 2021-04-13

Family

ID=66676901

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020011844A MX2020011844A (es) 2018-05-08 2019-05-08 Anticuerpos bispecificos con marcadores con emparejamiento de cargas c-terminales escindibles.

Country Status (8)

Country Link
US (1) US20220089756A1 (es)
EP (1) EP3790904A1 (es)
JP (2) JP2021523101A (es)
AU (1) AU2019265699A1 (es)
CA (1) CA3099450A1 (es)
MA (1) MA52571A (es)
MX (1) MX2020011844A (es)
WO (1) WO2019217587A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020304671A1 (en) * 2019-06-28 2022-01-20 Amgen Inc. Anti-CGRP receptor/anti-PAC1 receptor bispecific antigen binding proteins
WO2023141611A2 (en) * 2022-01-21 2023-07-27 Lyvgen Biopharma Holdings Limited Multi-specific antibodies in uses thereof in avidity receptor crosslinking and immune modulation

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DE19819846B4 (de) 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US7101692B2 (en) * 1999-04-15 2006-09-05 The Regents Of The University Of California Identification of sortase gene
CA2377513A1 (en) * 1999-06-25 2001-01-04 Universitat Zurich Hetero-associating coiled-coil peptides
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US8703132B2 (en) 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
WO2011034605A2 (en) * 2009-09-16 2011-03-24 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
AU2011245117B2 (en) * 2010-04-30 2015-03-12 Alexion Pharmaceuticals, Inc. Anti-C5a antibodies and methods for using the antibodies
US10851178B2 (en) * 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
JO3519B1 (ar) * 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
US10077299B2 (en) * 2013-04-25 2018-09-18 Abtlas Co., Ltd. Method for refining protein including self-cutting cassette and use thereof
BR112017026543A2 (pt) * 2015-08-26 2018-08-14 Bison Therapeutics Inc plataforma de anticorpo multiespecífico e métodos relacionados

Also Published As

Publication number Publication date
CA3099450A1 (en) 2019-11-14
JP2024023264A (ja) 2024-02-21
AU2019265699A1 (en) 2021-01-07
JP2021523101A (ja) 2021-09-02
EP3790904A1 (en) 2021-03-17
US20220089756A1 (en) 2022-03-24
WO2019217587A1 (en) 2019-11-14
MA52571A (fr) 2021-03-17

Similar Documents

Publication Publication Date Title
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
CO2018011668A2 (es) Neoantígenos y métodos de su uso
RU2020106752A (ru) Субстраты матриксной металлопротеиназы и другие расщепляемые фрагменты и способы их использования
CR20200171A (es) Contorsbodies 2 + 1 biespecíficos
MX2016011934A (es) Inmunoglobulina hibrida conteniendo un enlace no-peptidilico.
AR091069A1 (es) Proteinas de union a antigeno dirigidas contra el receptor st2
PE20140218A1 (es) Composicion farmaceutica
PE20221021A1 (es) Proteinas de union a antigeno que se unen especificamente a mage-a
EA201592006A1 (ru) Новые биспецифические связывающие молекулы с противоопухолевой активностью
PE20211272A1 (es) POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
AR077088A1 (es) Proteinas biespecificas de union a antigeno
RU2013110875A (ru) БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА, СОДЕРЖАЩИЕ СТАБИЛИЗИРОВАННЫЙ ДИСУЛЬФИДОМ ФРАГМЕНТ Fv
EA202190542A1 (ru) Сконструированные биспецифические белки
MX361076B (es) Proteínas multifunción que comprenden complejo mayor de histocompatibilidad (cmh) de clase i multivalente unido mediante disulfuro.
WO2018187356A3 (en) Protein antigens and uses thereof
MX2022000652A (es) Anticuerpos contra claudina 18 y metodos de tratamiento del cancer.
MX2020002921A (es) Anticuerpos para claudin6 y métodos para tratar el cáncer.
EA202091054A1 (ru) Слитые молекулы на основе антитела против pd-l1 и ил-7
MX2020010806A (es) Peptidos anti-inflamatorios y usos de los mismos.
EA201691782A1 (ru) Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
CL2018003072A1 (es) Anticuerpos anti-basigin humanizados y uso de los mismos.
EA201691779A1 (ru) Антитела, специфические к рецептору инсулиноподобного фактора роста 1, и их применения
MX2020011844A (es) Anticuerpos bispecificos con marcadores con emparejamiento de cargas c-terminales escindibles.
PH12019500802A1 (en) Antibodies that bind zika virus envelope protein and uses thereof
MX2021000155A (es) Moleculas de proteina multifuncionales que comprenden decorina y su uso.